Going (Way)back to the Future of Printed Publications

Posted by Janet Tse on Jun 2, 2017

Janet Tse

IPR challenges must rely on prior art “patents or printed publications” as the basis for invalidating US patents. But what if a useful prior art reference is not a typical printed publication such as a scientific literature reference or industry journal report? We explored the subject of what constitutes a prior art printed publication in a recent post; now we’ll take a closer look at this issue as it relates to digital content. Two related IPR decisions, Coalition for Affordable Drugs VIII, LLC v. The Trustees of the University of Pennsylvania (IPR2015-01835, Paper 56 and IPR2015-01836, Paper 58), demonstrate that it can sometimes be challenging to prove that a reference qualifies as a printed publication … leaving the petitioner wishing they could hop in the DeLorean to go back and change the prior art.

Read More

Topics: Kyle Bass, BioPharma, Printed Publications

Tough to Stomach: Differences in Kind and Differences in Degree

Posted by Jessica von Reyn on May 31, 2017

Jessica von Reyn

In IPRs, secondary considerations such as unexpected results can play a determinative role in evaluating obviousness, particularly when there is a clear nexus with the claimed invention. In general, ‘differences in degree’ of a known and expected property are not as persuasive in rebutting obviousness as ‘differences in kind’ (for example, a new property dissimilar to the known property). Such was the case in Coalition for Affordable Drugs v. Pozen, Inc. (IPR2015-01718), in a decision that may leave some feeling queasy. 

Read More

Topics: Kyle Bass, BioPharma

In IPRs, Section 112 Can Play a Critical Role—Even Late in the Game

Posted by Joseph Bowler on May 1, 2017

Joseph Bowler

As we’ve written before, notwithstanding statutory limits restricting IPR challenges to novelty and obviousness, Section 112 challenges are possible in an IPR. In several proceedings, petitioners have asserted references that have required the Board to determine whether an earlier filing supports the challenged patent’s claims. The Board generally has addressed these issues at the institution stage. However, a recent decision involving Kyle Bass and his Coalition for Affordable Drugs demonstrates the Section 112 analysis may not be fully resolved until the trial stage, where it can play a determinative role.

Read More

Topics: Kyle Bass, BioPharma

Magnitude of Comparative Results: What’s Considered Unexpected?

Posted by Jean Ge on Apr 24, 2017

Jean Ge

The discovery of an optimum value of a “result-effective variable” in a known process is ordinarily considered within the skill of the art and obvious. But, if a patent owner shows that optimizing the variable resulted in benefits with a magnitude unexpected by one skilled in the art, the optimized variable may be found nonobvious, as in Coalition For Affordable Drugs v. Biogen Idec Inc. (IPR2015-01993).

Read More

Topics: Kyle Bass, BioPharma

Avoid Ulcers by Crafting a Well-Reasoned Petition

Posted by Meghan Adams on Apr 13, 2017

Meghan Adams

Your IPR petition argues that a patent is obvious—but will those arguments even be fully considered? A recent decision in Affordable Drugs VII v. Pozen Inc. emphasizes the importance of providing evidence-based arguments within the appropriate documents that inform the Board’s investigation.

Read More

Topics: Kyle Bass, BioPharma

Fighting Fungi: When Comparative Evidence Is A Must

Posted by Amy McMahon on Mar 22, 2017

Amy McMahon

It is well established that objective evidence of nonobviousness (e.g., commercial success, long-felt but unresolved needs, unexpected results, etc.) must be taken into account when evaluating the obviousness of a claimed invention. This standard applies during patent prosecution, in proceedings before the PTAB, and in litigation. However, as demonstrated by a recent IPR decision involving Kyle Bass’s Coalition for Affordable Drugs (IPR2015-01776), it can be can be challenging to provide sufficient evidence of unexpected results and long-felt need.

Read More

Topics: Kyle Bass, BioPharma

A Rose ‘Whereby’ Any Other Name Would Smell as Sweet to a Petitioner

Posted by Ed Walsh on Nov 29, 2016

Ed Walsh

In Coalition for Affordable Drugs v. Pozen, Inc. (IPR2015-01718), the Board instituted a trial despite a failure of the petition to show that a final “wherein” clause of a method claim was met by the prior art. Rather, the Board reasoned that the “wherein” clause was likely to actually be a “whereby” clause, just by another name. Because a “whereby” clause stating the intended result of performing a method is not a limitation on the claim, failure to show that the result was known or even occurred in the prior art was not a basis to deny institution.

Read More

Topics: Kyle Bass, BioPharma

Bass Gets a Bite

Posted by Tom Chlebeck on Oct 15, 2015

Tom Chlebeck

Last week, in a decision that has surprised and worried some, the Board instituted one of the numerous IPRs for which Kyle Bass and the Coalition for Affordable Drugs (IPR2015-00988) filed petitions. Previously, the Board had been able to deny some of Bass’s petitions based on the petitions’ failure to demonstrate that references qualified as prior art (which we discussed here). However, the Board later declined to sanction Bass for abuse of process and misuse of proceedings in filing other similar petitions (which we discussed here).

Read More

Topics: Kyle Bass

Board Opens the Floodgates to Let Bass Through

Posted by John Harmon on Oct 2, 2015

John Harmon

Kyle Bass and the Coalition for Affordable Drugs have scored a big win in the multiple IPRs they filed to invalidate Celgene Corp.’s patents and ultimately profit by shorting its stock. The Board has ruled against imposing the sanctions Celgene requested against Bass for improper purpose and/or abuse of process, clearing the way for all of the IPRs to proceed. The reasons advanced in the ruling may open up the IPR process to entities well beyond those that have traditionally used procedures at the Patent Office to invalidate patents.

Read More

Topics: Petitioners, Kyle Bass, Patent Owners

Board Tells Bass to “Go Fish”

Posted by Nathan Speed on Aug 25, 2015

Nathan Speed

In the much-anticipated first Board decision to address the merits of an IPR petition filed by the Coalition for Affordable Drugs and Kyle Bass, the Board yesterday denied institution in IPR2015-00720. The reason for the denial was simpler than some of the arguments advanced by the patent owner, and serves as a reminder to petitioners of their burden to demonstrate that relied upon references are prior art.

Read More

Topics: Kyle Bass

Wolf Greenfield's Post-Grant Blog

Here, the Post-Grant Proceedings Group
at Wolf Greenfield keeps you up to date
on the latest decisions and best practices, and what they mean for you. Learn more about the group and its members.

New Call-to-action
New Call-to-action
New Call-to-action

Subscribe to Email Updates

Recent Posts

Follow Us

This blog is intended to promote thought and debate on developing areas of the law. The opinions, commentary and characterizations of cases provided on this blog are not legal advice and do not represent the opinions of Wolf Greenfield or its clients.